AU2010224587A1 - Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid - Google Patents

Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid Download PDF

Info

Publication number
AU2010224587A1
AU2010224587A1 AU2010224587A AU2010224587A AU2010224587A1 AU 2010224587 A1 AU2010224587 A1 AU 2010224587A1 AU 2010224587 A AU2010224587 A AU 2010224587A AU 2010224587 A AU2010224587 A AU 2010224587A AU 2010224587 A1 AU2010224587 A1 AU 2010224587A1
Authority
AU
Australia
Prior art keywords
udca
patients
nash
months
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010224587A
Other languages
English (en)
Inventor
Vlad Ratziu
Marc Riviere
Jean Spenard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptalis Pharma Canada ULC
Original Assignee
Axcan Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcan Pharma Inc filed Critical Axcan Pharma Inc
Publication of AU2010224587A1 publication Critical patent/AU2010224587A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010224587A 2009-03-17 2010-03-16 Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid Abandoned AU2010224587A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16095509P 2009-03-17 2009-03-17
US61/160,955 2009-03-17
PCT/IB2010/000551 WO2010106420A1 (en) 2009-03-17 2010-03-16 Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid

Publications (1)

Publication Number Publication Date
AU2010224587A1 true AU2010224587A1 (en) 2011-09-22

Family

ID=42167374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010224587A Abandoned AU2010224587A1 (en) 2009-03-17 2010-03-16 Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid

Country Status (12)

Country Link
US (1) US20120071451A1 (enExample)
EP (1) EP2408457A1 (enExample)
JP (1) JP2012520866A (enExample)
KR (1) KR20120008034A (enExample)
CN (1) CN102361642A (enExample)
AU (1) AU2010224587A1 (enExample)
CA (1) CA2755708A1 (enExample)
IL (1) IL215195A0 (enExample)
MX (1) MX2011009757A (enExample)
RU (1) RU2011139643A (enExample)
WO (1) WO2010106420A1 (enExample)
ZA (1) ZA201107578B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
KR101401628B1 (ko) * 2012-12-24 2014-06-02 삼성제약공업주식회사 간기능 개선용 정제 및 그 제조 방법
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
KR20250008786A (ko) * 2014-07-29 2025-01-15 센젠 하이타이드 바이오파마슈티컬 리미티드 베르베린 염, 우르소데옥시콜산 염 및 병용물, 이들의 제조 및 응용 방법
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CN107613968A (zh) * 2015-11-19 2018-01-19 欣耀生医股份有限公司 预防或治疗脂肪肝的药物组合物
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
SG10202104575WA (en) 2016-11-04 2021-06-29 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
JP2020524684A (ja) * 2017-06-21 2020-08-20 ノバルティス アーゲー 非アルコール性脂肪性肝炎の治療のためのリコフリゴジン
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
KR101887561B1 (ko) * 2017-11-15 2018-09-06 주식회사 대웅제약 간염 바이러스에 의해 유발된 간 섬유화의 개선을 위한 약학 조성물
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
RU2686042C1 (ru) * 2018-09-04 2019-04-23 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ лечения неалкогольной жировой болезни печени при метаболическом синдроме
CN112823012A (zh) 2018-09-12 2021-05-18 儿童医院医学中心 用于产生造血干细胞及其衍生物的类器官组合物
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
US12534709B2 (en) 2019-05-31 2026-01-27 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CA3141807A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
CN114207143A (zh) * 2019-07-30 2022-03-18 Ko生物技术有限公司 预测或诊断非酒精性脂肪肝病的试剂盒及诊断非酒精性脂肪肝病的方法
WO2021020923A1 (ko) * 2019-07-30 2021-02-04 주식회사 고바이오랩 간 손상 예방, 개선, 또는 치료용 조성물 및 간 손상 예방, 개선, 또는 치료방법
PH12022551256A1 (en) * 2020-01-28 2023-11-20 Shilpa Medicare Ltd Method for administration of ursodeoxycholic acid
WO2022083713A1 (en) * 2020-10-23 2022-04-28 Shenzhen Hightide Biopharmaceutical Ltd. Compositions of berberine ursodeoxycholate and methods thereof for treating fatty liver disease, diabetes and hyperlipidemia
CN115137732A (zh) * 2021-03-29 2022-10-04 中国科学院大连化学物理研究所 Gpr120受体激动剂及熊去氧胆酸的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297229B1 (en) * 1994-11-14 2001-10-02 Mayo Foundation For Medical Education And Research Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis

Also Published As

Publication number Publication date
WO2010106420A1 (en) 2010-09-23
US20120071451A1 (en) 2012-03-22
ZA201107578B (en) 2013-06-26
IL215195A0 (en) 2011-12-29
CA2755708A1 (en) 2010-09-23
KR20120008034A (ko) 2012-01-25
MX2011009757A (es) 2012-02-28
CN102361642A (zh) 2012-02-22
EP2408457A1 (en) 2012-01-25
JP2012520866A (ja) 2012-09-10
RU2011139643A (ru) 2013-04-27

Similar Documents

Publication Publication Date Title
US20120071451A1 (en) Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid
JP6431959B2 (ja) エンパグリフロジンの治療的使用
RU2623023C2 (ru) Ликсисенатид и метформин для лечения диабета типа 2
JP6561136B2 (ja) 勃起機能不全を治療又は改善するための方法及びｓｇｌｔ２阻害薬を含む医薬組成物
JP2019123716A (ja) 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法
CA3118961A1 (en) Combination treatment of nafld and nash
Portincasa et al. Current pharmacological treatment of nonalcoholic fatty liver
Feingold et al. Oral and injectable (non-insulin) pharmacological agents for type 2 diabetes
JP2013540801A (ja) 代謝異常の治療のための組合せ医薬
EP2063890A1 (en) Combination treatment for diabetes mellitus
JP2016515600A (ja) エンパグリフロジンの治療的使用
CN106714840A (zh) 用于治疗肝病的ω‑3脂肪酸和SGLT‑2抑制剂的组合
US20230131804A1 (en) Farnesoid x receptor agonists for the treatment of disease
JP2017504649A5 (enExample)
TW201705974A (zh) 第２型糖尿病病患治療
Park et al. Two-year therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and empagliflozin in drug-naïve type 2 diabetes mellitus patients
Nogueira et al. Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease
TW202114654A (zh) 包含如sglt 1/2抑制劑的sglt抑制劑之治療
RU2653478C2 (ru) Способ улучшения функции печени
Krentz Management of type 2 diabetes in the obese patient: current concerns and emerging therapies
WO2021188690A1 (en) Farnesoid x receptor agonists for the treatment of disease
WO2024243951A1 (zh) 川芎嗪硝酮衍生物在预防或治疗2型糖尿病中的应用
WO2024263537A1 (en) Use of a long-acting oxyntomodulin derivative for treament of fatty liver disease
CN116761597A (zh) 司拉德帕治疗胆管病
Ludvik State-of-the-art and future aspects of the treatment of type 2 diabetes mellitus

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application